Atherotech offers galectin-3 testing services

Atherotech leverages BGM Galectin-3 test to offer galectin-3 testing.

The BGM Galectin-3 test was cleared as an aid in assessing the prognosis of patients diagnosed with chronic heart failure, by the US Food and Drug Administration in November 2010.

The launch of galectin-3 testing by Atherotech represents further expansion of the availability of galectin-3 testing to practicing physicians in the US, according to the company.

BG Medicine is a life sciences company focused on the discovery, development and commercialization of novel cardiovascular diagnostics to address unmet medical needs, improve patient outcomes and contain healthcare costs.